Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Ventolin Evohaler 100 micrograms

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Salbutamol sulfate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Salbutamol sulfate

Equivalent medicines (same active substance, strength and form)

Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for

Ventolin Evohaler contains a medicine called salbutamol. This belongs to a group of medicines called fast-acting bronchodilators.

  • Bronchodilators help the airways in your lungs to stay open. This makes it easier for air to get in and out.
  • They help to relieve chest tightness, wheezing and cough. Ventolin Evohaler is used to treat breathing problems in people with asthma and similar conditions. This includes relieving and preventing asthma brought on by exercise or other "triggers". These are things, which bring on asthma symptoms in some people. Common triggers include house dust, pollen, cats, dogs and cigarette smoke. In asthma, fast-acting bronchodilators including Salbutamol Evohaler should not be the main or only treatment. It is recommended that Salbutamol Evohaler should always be prescribed with an inhaled corticosteroid (anti-inflammatory) medicine.

2

What you need to know before you take it

e Ventolin Evohaler

Do not use Ventolin Evohaler if:

  • you are allergic to salbutamol sulfate or any of the other ingredients of this medicine (listed in section 6).
  • you unexpectedly go into early labour (premature labour) or threatened abortion. Ventolin Evohaler should be used as required rather than regularly. Warnings and precautions Talk to your doctor, nurse or pharmacist before taking Ventolin Evohaler if:
  • your asthma is active (for example you have frequent symptoms or flare ups, such as breathlessness that makes speaking, eating or sleeping difficult, cough, wheezing, tight chest or limited physical ability), you should tell your doctor right away who may start or increase a medicine to control your asthma such as an inhaled corticosteroid. -1-

• • • • •

you have high blood pressure. you have an overactive thyroid gland. you have a history of heart problems such as an irregular or fast heartbeat or angina. you are taking xanthine derivatives (such as theophylline) or steroids to treat asthma. you are taking water tablets (diuretics), sometimes used to treat high blood pressure or a heart condition.

Your inhaler does not have a dose counter. Your inhaler contains enough medicine for 200 puffs only (whether inhaled and/or released into the air for testing) and it contains a propellant gas to deliver the medicine. However, after 200 puffs, your inhaler can continue to spray the gas but without the right dose of salbutamol, so you cannot be sure you will receive any medicine after using 200 puffs. Methods of telling that the inhaler is empty like shaking it, weighing it, or floating it in water, are not reliable. You should consider recording the number of puffs used. You could also consider keeping a back-up inhaler. If you are using more than one inhaler, it is recommended to keep track of the number of puffs used for each inhaler separately.

  • If your inhaler fails to give relief for a duration of at least 3 hours, check with your doctor as soon as possible.
  • Tell your doctor as soon as possible if your asthma gets worse or if this medicine does not provide as much relief from your asthma as before. Other medicines and Ventolin Evohaler Tell your doctor, nurse or pharmacist if you are taking, have recently taken or might take other medicines, including medicines obtained without a prescription. This includes herbal medicines. Remember to take this medicine with you if you have to go to hospital. In particular tell your doctor, nurse or pharmacist if you are taking:
  • medicines for an irregular or fast heartbeat
  • other medicines for your asthma. Ventolin Evohaler with food and drink You can take Ventolin Evohaler at any time of day, with or without food. Pregnancy, breast-feeding and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor, nurse or pharmacist for advice before taking this medicine. Driving and using machines Ventolin is not likely to affect you being able to drive or use any tools or machines.

3

How to take it

Ventolin Evohaler

Always use this medicine exactly as your doctor has told you. Check with your doctor, nurse or pharmacist if you are not sure. Adults and adolescents aged 12 years and over

  • to relieve asthma symptoms/ attack – One or two puffs.
  • to prevent asthma symptoms/ attack – Two puffs 10-15 minutes before exercise or exposure to a "trigger".
  • for regular treatment (along with regular asthma anti-inflammatory medicine – inhaled corticosteroid) – One or two puffs. ➔

The maximum dose is 800 micrograms (two puffs up to four times in a 24 hour period).

Children under 12 years of age

  • to relieve asthma symptoms/ attack – One puff. Two puffs if required. -2-

• •

➔

to prevent asthma symptoms/ attack – One puff 10-15 minutes before exercise or exposure to a "trigger". Two puffs if required. for regular treatment (along with regular asthma anti-inflammatory medicine – inhaled corticosteroid) – One or two puffs. The maximum dose is 800 micrograms (two puffs up to four times in a 24 hour period).

Instructions for use The inhaler does not have a dose counter, you can consider recording the number of puffs you are taking. If you are using more than one inhaler, it is recommended to keep track of the number of doses for each inhaler separately. • • •

To help identify that the inhaler is Ventolin, there is an embossed letter V on the plastic case. Ventolin Evohaler produces a fine mist, which you inhale through your mouth into your lungs. Your doctor, nurse or pharmacist should show you how to use your inhaler. If you are not sure ask your doctor, nurse or pharmacist. Each Evohaler canister provides 200 puffs.

Do not use your inhaler more often than the doctor told you to. Tell your doctor as soon as possible if your medicine does not seem to be working as well as usual (for example you need higher doses to relieve your breathing problems or your inhaler fails to give relief for at least 3 hours) as your chest problem may be getting worse and you may need a different medicine. If you use Ventolin Evohaler more than twice a week to treat your asthma symptoms, not including preventive use before exercise, this indicates poorly controlled asthma and may increase the risk of severe asthma attacks (worsening of asthma) that can have serious complications and may be life-threatening or even fatal. You should contact your doctor as soon as possible to review your asthma treatment. If you use a medicine against inflammation of your lungs daily, e.g., "inhaled corticosteroid", it is important to continue using it regularly, even if you feel better. Your doctor may have told you to take more than this as an emergency treatment if your wheezing or breathing gets very bad. It is very important that you keep to your doctor's instructions as to how many puffs to take and how often to use your inhaler.

-3-

Testing your inhaler 1 When using the inhaler for the first time, test that it is working. Remove the mouthpiece cover by gently squeezing the sides with your thumb and forefinger and pull apart. 2 To make sure that it works, shake it well, point the mouthpiece away from you and press the canister to release two puffs into the air. If you have not used the inhaler for 5 days or more, shake it well and release two puffs of medicine into the air. Using your inhaler It is important to start to breathe as slowly as possible just before using your inhaler. 1 Stand or sit upright when using your inhaler. 2 Remove the mouthpiece cover (as shown in the first picture). Check inside and outside to make sure that the mouthpiece is clean and free of objects.

3 Shake the inhaler 4 or 5 times to ensure that any loose objects are removed and that the contents of the inhaler are evenly mixed.

4 Hold the inhaler upright with your thumb on the base, below the mouthpiece. Breathe out as far as is comfortable. Do not breathe in again yet.

-4-

5 Place the mouthpiece in your mouth between your teeth. Close your lips around it. Do not bite.

6 Breathe in through your mouth. Just after starting to breathe in, press down on the top of the canister to release a puff of medicine. Do this while still breathing in steadily and deeply.

7 Hold your breath, take the inhaler from your mouth and your finger from the top of the inhaler. Continue holding your breath for a few seconds, or as long as is comfortable.

8 If your doctor has told you to take two puffs, wait about half a minute before you take another puff by repeating steps 3 to 7. 9 After use always replace the mouthpiece cover straight away to keep out dust. Replace the cover by firmly pushing and clicking into position. Practise in front of a mirror for the first few times. If you see a 'mist' coming from the top of your inhaler or the sides of your mouth you should start again. Young children may need help and their parents may need to operate the inhaler for them. Encourage the child to breathe out and operate the inhaler just after the child starts to breathe in. Practise the technique together. You may find the Volumatic spacer device, with a face mask, or the Babyhaler device useful if you have to give Ventolin Evohaler to a baby or a child under 5 – speak to your doctor if you think you might need one of these. Older children or people with weak hands may find it easier to hold the inhaler with both hands. Put the two forefingers on top of the inhaler and both thumbs on the bottom below the mouthpiece. If this does not help, your doctor, nurse or pharmacist will be able to advise you.

-5-

Cleaning your inhaler To stop your inhaler blocking, it is important to clean it at least once a week. To clean your inhaler:

  • Remove the metal canister from the plastic casing of the inhaler and remove the mouthpiece cover.
  • Rinse the plastic casing thoroughly under warm running water.
  • Dry the plastic casing thoroughly inside and out.
  • Replace the metal canister into the plastic casing and put on mouthpiece cover. Do not put the metal canister in water. If you take more Ventolin Evohaler than you should If you take more than you should, talk to a doctor as soon as possible. The following effects may happen:
  • your heart beating faster than usual
  • you feel shaky.
  • hyperactivity These effects usually wear off in a few hours. If you forget to take Ventolin Evohaler
  • If you forget a dose, take it as soon as you remember it.
  • However, if it is time for the next dose, skip the missed dose.
  • Do not take a double dose to make up for a forgotten dose. If you stop taking Ventolin Evohaler Do not stop taking Ventolin Evohaler without talking to your doctor. If you have any further questions on the use of this medicine, ask your doctor, nurse or pharmacist.

4

4 Possible side effects

If your breathing or wheezing gets worse straight after taking this medicine, stop using it immediately, and tell your doctor as soon as possible. Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may happen with this medicine: Allergic Reactions (may affect up to 1 in 10,000 people) If you have an allergic reaction, stop taking Ventolin Evohaler and see a doctor straight away. Signs of an allergic reaction include: swelling of the face, lips, mouth, tongue or throat which may cause difficulty in swallowing or breathing, itchy rash, feeling faint and light headed, and collapse. Talk to your doctor as soon as possible if:

  • you feel your heart is beating faster or stronger than usual (palpitations). This is usually harmless, and usually stops after you have used the medicine for a while
  • you may feel your heartbeat is uneven or it gives an extra beat
  • these may affect up to 1 in 10 people. If any of these happen to you, talk to your doctor as soon as possible. Do not stop using this medicine unless told to do so. Tell your doctor if you have any of the following side effects which may also happen with this

-6-

medicine: Common (may affect up to 1 in 10 people)

  • feeling shaky
  • headache. Uncommon (may affect up to 1 in 100 people)
  • mouth and throat irritation
  • muscle cramps. Rare (may affect up to 1 in 1,000 people)
  • a low level of potassium in your blood
  • increased blood flow to your extremities (peripheral dilatation). Very rare (may affect up to 1 in 10,000 people)
  • changes in sleep patterns and changes in behaviour, such as restlessness and excitability. The following side effects can also happen but the frequency of these are not known:
  • chest pain, due to heart problems such as angina. Tell your doctor, nurse or pharmacist if this occurs. Do not stop using this medicine unless told to do so. Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any

Possible side effects

not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard By reporting side effects you can help provide more information on the safety of this medicine. If you think this medicine is not working well enough for you If your medicine does not seem to be working as well as usual, talk to your doctor as soon as possible. Your chest problem may be getting worse and you may need a different medicine. Do not take extra doses of Ventolin Evohaler unless your doctor tells you to.

5

How to store it

Ventolin Evohaler

• • •

Keep this medicine out of the sight and reach of children. Store below 30°C. Protect from frost and direct sunlight. If the inhaler gets very cold, take the metal canister out of the plastic case and warm it in your hands for a few minutes before use. Never use anything else to warm it up. The metal canister is pressurised. Do not expose to temperatures higher than 50oC. Do not puncture, break or burn the inhaler even when it is empty. Do not use this medicine after the expiry date, which is stated on the label and carton after 'EXP'. The expiry date refers to the last day of that month.

• •

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.

6

Contents of the pack and other information

What Ventolin Evohaler contains

  • The active substance is salbutamol sulfate.
  • The other ingredient is HFA 134a. This medicine contains fluorinated greenhouse gases. Each inhaler contains 18 g of HFC-134a (also referred as HFA 134a) corresponding to 0.0257 tonne -7-

CO2 equivalent (global warming potential GWP = 1 430). What Ventolin Evohaler looks like and contents of the pack Ventolin Evohaler comprises an aluminium alloy can sealed with a metering valve, actuator and dust cap. Each canister contains 200 doses (whether inhaled and/or released into the air for testing) of 100 micrograms of salbutamol (as salbutamol sulfate). Marketing Authorisation Holder Glaxo Wellcome UK Limited GSK Medicines Research Centre Gunnels Wood Road Stevenage Hertfordshire SG1 2NY UK Manufacturer Glaxo Wellcome, S.A. Aranda de Duero Burgos Spain

Glaxo Wellcome Production Zone Industrielle No. 2 23 rue Lavoisier 27000 – Evreux France

Other formats: To listen to or request a copy of this leaflet in Braille, large print or audio please call, free of charge:

0800 198 5000 (UK only) Please be ready to give the following information: Product name Reference number

Ventolin Evohaler PL 10949/0274

This is a service provided by the Royal National Institute of Blind People. This leaflet was last revised in September 2025 Ventolin and Evohaler are registered trade marks of the GSK group of companies. © 2025 GSK group of companies. All rights reserved.

-8-

Asthma Control Test The Asthma Control Test is one way to quickly assess your asthma control, giving you a simple score out of 25. Your healthcare professional may ask you additional questions during a consultation. Are you in control of your asthma? Or is your asthma in control of you? Here's how to find out Step 1: Read each question below carefully, circle your score and write it in the box. Step 2: Add up each of your five scores to get your total Asthma Control TestTM score. Step 3: Use the score guide to learn how well you are controlling your asthma.

What does your score mean? Score: 25 – WELL DONE • •

Your asthma appears to have been UNDER CONTROL over the last 4 weeks. However, if you are experiencing any problems with your asthma, you should see your doctor, nurse or pharmacist.

Score: 20 to 24 – ON TARGET • •

Your asthma appears to have been REASONABLY WELL CONTROLLED during the past 4 weeks. However, if you are experiencing symptoms your doctor, nurse or pharmacist may be able to help you.

-9-

Score: less than 20 – OFF TARGET • •

Your asthma may NOT HAVE BEEN CONTROLLED during the past 4 weeks. Your doctor, nurse or pharmacist can recommend an asthma action plan to help improve your asthma control.

© 2002, by Quality Metric Incorporated. Asthma Control Test is a trademark of Quality Metric Incorporated

  • 10 –

Frequently asked questions about Ventolin Evohaler 100 micrograms

What is the active substance in Ventolin Evohaler 100 micrograms?

The active substance in Ventolin Evohaler 100 micrograms is salbutamol sulfate.

Are there equivalent medicines to Ventolin Evohaler 100 micrograms?

Medicines with the same active substance, strength and form include: Easyhaler Salbutamol 100mcg. They are interchangeable only if your prescriber or pharmacist says so.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Ventolin Evohaler 100 micrograms, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Ventolin Evohaler 100 micrograms without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Salbutamol sulfate (16 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Ventolin Evohaler is indicated in adults, adolescents and children aged 4 to 11 years. For babies and children under 4 years of age, see sections 4.2 and 5.1.

Ventolin Evohaler provides short-acting (4 to 6 hour) bronchodilation with fast onset (within 5 minutes) in reversible airways obstruction.

It is particularly suitable for the relief and prevention of bronchospasm. It should be used to relieve symptoms when they occur, and to prevent them in those circumstances recognised by the patient to precipitate an asthma attack (e.g. before exercise or unavoidable allergen exposure).

In asthma, short acting beta-2 agonists including Salbutamol Evohaler should not be the main or only treatment. It is recommended that short acting beta-2 agonists should be prescribed with concomitant inhaled corticosteroid (anti-inflammatory).

4.2. Posology and method of administration

Ventolin Evohaler is for oral inhalation use only. Ventolin Evohaler may be used with a Volumatic spacer device by patients who find it difficult to synchronise aerosol actuation with inspiration of breath.

Adults (including the elderly):

For the relief of acute asthma symptoms including bronchospasm, one inhalation (100 micrograms) may be administered as a single minimum starting dose. This may be increased to two inhalations if necessary. To prevent allergen- or exercise-induced symptoms, two inhalations should be taken 10-15 minutes before challenge.

For chronic therapy, two inhalations up to four times a day.

Paediatric Population

Relief of acute bronchospasm

The usual dosage for children under the age of 12 years: one inhalation (100 micrograms). The dose may be increased to two inhalations if required.

Children aged 12 years and over: dose as per adult population.

Prevention of allergen or exercise-induced bronchospasm

The usual dosage for children under the age of 12 years: one inhalation (100 micrograms) before challenge or exertion. The dose may be increased to two inhalations if required.

Children aged 12 years and over: dose as per adult population.

Chronic therapy

The usual dosage for children under the age of 12 years: up to two inhalations 4 times daily.

Children aged 12 years and over: dose as per adult population.

The Babyhaler spacer device may be used to facilitate administration to children under 5 years of age.

On-demand use of Ventolin Evohaler should not exceed 8 inhalations in any 24 hours. Reliance on such frequent supplementary use, or a sudden increase in dose, indicates poorly controlled or deteriorating asthma (see section 4.4).

4.3. Contraindications

Hypersensitivity to the active substance or any of the excipients listed in section 6.1.

Non-i.v. formulations of salbutamol must not be used to arrest uncomplicated premature labour or threatened abortion.

4.4. Special warnings and precautions for use

Patients inhaler technique should be checked to make sure that aerosol actuation is synchronised with inspiration of breath for optimum delivery of drug to the lungs. Patients should be warned that they may experience a different taste upon inhalation compared to their previous inhaler.

The inhaler contains enough salbutamol for a total of 200 actuations (puffs) only. After the 200 actuations (puffs) have been used, the inhaler can when actuated continue to release a spray of propellant which no longer contains the prescribed dose of salbutamol. Methods such as shaking, weighing or submerging inhalers are not accurate for determining that an inhaler is empty of the prescribed dose of salbutamol. To avoid inadvertent use of an empty inhaler, maintaining a record of the number of actuations (puffs) administered to the patient should be considered. Keeping a back-up inhaler could also be considered. If the patient has more than one inhaler, it is recommended to keep track of doses administrated from each inhaler separately (see section 6.6).

Bronchodilators should not be the only or main treatment in patients with severe or unstable asthma. Severe asthma requires regular medical assessment, including lung-function testing, as patients are at risk of severe attacks and even death. Physicians should consider using the maximum recommended dose of inhaled corticosteroid and/or oral corticosteroid therapy in these patients.

The dosage or frequency of administration should only be increased on medical advice. If a previously effective dose of inhaled salbutamol no longer provides relief for a duration of three hours following administration, the patient should be advised to promptly seek medical advice.

Failing to respond to treatment with salbutamol may signal a need for urgent medical advice or treatment.

Patients who are prescribed regular anti-inflammatory therapy (e.g., inhaled corticosteroids) should be advised to continue taking their anti-inflammatory medication even when symptoms decrease, and they do not require Ventolin Evohaler.

Increasing use of bronchodilators, in particular short-acting inhaled beta-2-agonists, to relieve symptoms, indicates deterioration of asthma control, and patients should be warned to seek medical advice as soon as possible. The patient should be instructed to seek medical advice if short-acting relief bronchodilator treatment becomes less effective, or more inhalations than usual are required. In this situation the patient should be assessed and consideration given to the need for increased anti-inflammatory therapy (e.g. higher doses of inhaled corticosteroid or a course of oral corticosteroid).

Overuse of short-acting beta-agonists may mask the progression of the underlying disease and contribute to deteriorating asthma control, leading to an increased risk of severe asthma exacerbations and mortality.

Patients who take more than twice a week “as needed” salbutamol, not counting prophylactic use prior to exercise, should be re-evaluated (i.e., daytime symptoms, night-time awakening, and activity limitation due to asthma) for proper treatment adjustment as these patients are at risk for overuse of salbutamol.

Severe exacerbations of asthma must be treated in the normal way.

Cardiovascular effects may be seen with sympathomimetic drugs, including salbutamol. There is some evidence from post-marketing data and published literature of rare occurrences of myocardial ischaemia associated with salbutamol. Patients with underlying severe heart disease (e.g. ischaemic heart disease, arrhythmia or severe heart failure) who are receiving salbutamol should be warned to seek medical advice if they experience chest pain or other symptoms of worsening heart disease. Attention should be paid to assessment of symptoms such as dyspnoea and chest pain, as they may be of either respiratory or cardiac origin.

Salbutamol should be administered cautiously to patients with thyrotoxicosis.

Potentially serious hypokalaemia may result from beta-2-agonist therapy, mainly from parenteral and nebulised administration. Particular caution is advised in acute severe asthma as this effect may be potentiated by hypoxia and by concomitant treatment with xanthine derivatives, steroids and diuretics. Serum potassium levels should be monitored in such situations.

As with other inhalation therapy, paradoxical bronchospasm may occur with an immediate increase in wheezing after dosing. This should be treated immediately with an alternative presentation or a different fast-acting inhaled bronchodilator. Evohaler should be discontinued immediately, the patient assessed, and if necessary, a different fast-acting bronchodilator instituted for on-going use.

4.5. Interaction with other medicinal products and other forms of interaction

Salbutamol and non-selective β-blocking drugs such as propranolol, should not usually be prescribed together.

4.6. Fertility, pregnancy and lactation

Pregnancy

Studies in animals have shown reproductive toxicity (see section 5.3). Safety in pregnant women has not been established. No controlled clinical trials with salbutamol have been conducted in pregnant women. Rare reports of various congenital anomalies following intrauterine exposure to salbutamol (including cleft palate, limb defects and cardiac disorders) have been received. Some of the mothers were taking multiple medications during their pregnancies. Ventolin Evohaler should not be used during pregnancy unless clearly necessary.

Breast-feeding

As salbutamol is probably secreted in breast milk, its use in nursing mothers requires careful consideration. It is not known whether salbutamol has a harmful effect on the neonate, and so its use should be restricted to situations where it is felt that the expected benefit to the mother is likely to outweigh any potential risk to the neonate.

Fertility

There is no information on the effects of salbutamol on human fertility. There were no adverse effects on fertility in animals (see section 5.3).

4.7. Effects on ability to drive and use machines

None reported.

4.8. Undesirable effects

Adverse events are listed below by system organ class and frequency. Frequencies are defined as: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1000 to <1/100), rare (≥1/10,000 to <1/1000) and very rare (<1/10,000) including isolated reports. Very common and common events were generally determined from clinical trial data. Rare, very rare and unknown events were generally determined from spontaneous data.

Immune system disorders

Very rare:

Hypersensitivity reactions including angioedema, urticaria, bronchospasm, hypotension and collapse.

Metabolism and nutrition disorders

Rare:

Hypokalaemia.

Potentially serious hypokalaemia may result from beta-2 agonist therapy.

Nervous system disorders

Common:

Tremor, headache.

Very rare:

Hyperactivity.

Cardiac disorders

Common:

Tachycardia.

Uncommon:

Palpitations.

Very rare:

Cardiac arrhythmias (including atrial fibrillation, supraventricular tachycardia and extrasystoles).

Unknown:

Myocardial ischaemia* (see section 4.4)

Vascular disorders

Rare:

Peripheral vasodilatation.

Respiratory, thoracic and mediastinal disorders

Very rare:

Paradoxical bronchospasm.

Gastrointestinal disorders

Uncommon:

Mouth and throat irritation.

Musculoskeletal and connective tissue disorders

Uncommon:

Muscle cramps.

* reported spontaneously in post-marketing data therefore frequency regarded as unknown

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.

4.9. Overdose

The most common signs and symptoms of overdose with salbutamol are transient beta agonist pharmacologically mediated events, including tachycardia, tremor, hyperactivity and metabolic effects including hypokalaemia (see sections 4.4 and 4.8).

Hypokalaemia may occur following overdose with salbutamol. Serum potassium levels should be monitored. Lactic acidosis has been reported in association with high therapeutic doses as well as overdoses of short-acting beta-agonist therapy, therefore monitoring for elevated serum lactate and consequent metabolic acidosis (particularly if there is persistence or worsening of tachypnea despite resolution of other signs of bronchospasm such as wheezing) may be indicated in the setting of overdose.

💬 Ask about this leaflet

Ask anything about Ventolin Evohaler 100 micrograms. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →